Öz
Background: The use of
hemostatic agents is used to stop the bleeding. In medicine, an ideal
hemostatic agent should have been stop venous bleeding after being applied to
the lesion. This study investigated the
in vitro effects of A-Fact a hemostatic parameter. Methods: It has been determined in human plasma at different
rates. Hemostatic parameters were determined using routine biochemical methods. For
morphological evaluation in full blood, microscopic images of 5%, 10%, 15% and
50% drugs applied to blood samples were taken. Results: A-Fact
induced the very fast formation of protein network. Coagulation test was
performed on 2/20 dilution. The coagulation factor (II, VII, IX) was studied. The
levels of coagulation factors were not affected by A-Fact. Plasma fibrinogen
activities, total protein, albumin and globulin levels decreased, in parallel
and with the prolonged prothrombin time. And also INR values were increased
following the addition of the A-Fact. Conclusion: Our results suggested that the mechanism of A-Fact bleeding stopper has shown the formation of the
protein network. These data support that A-Fact may be evaluated as a new
hemostatic agent.Background: The use of
hemostatic agents is used to stop the bleeding. In medicine, an ideal
hemostatic agent should have been stop venous bleeding after being applied to
the lesion. This study investigated the
in vitro effects of A-Fact a hemostatic parameter. Methods: It has been determined in human plasma at different
rates. Hemostatic parameters were determined using routine biochemical methods. For
morphological evaluation in full blood, microscopic images of 5%, 10%, 15% and
50% drugs applied to blood samples were taken. Results: A-Fact
induced the very fast formation of protein network. Coagulation test was
performed on 2/20 dilution. The coagulation factor (II, VII, IX) was studied. The
levels of coagulation factors were not affected by A-Fact. Plasma fibrinogen
activities, total protein, albumin and globulin levels decreased, in parallel
and with the prolonged prothrombin time. And also INR values were increased
following the addition of the A-Fact. Conclusion: Our results suggested that the mechanism of A-Fact bleeding stopper has shown the formation of the
protein network. These data support that A-Fact may be evaluated as a new
hemostatic agent.
Anahtar Kelimeler
Kaynakça
- 1. Ferhanoğlu B. Hemostaz Mekanizması. Hematoloji Ders Kitabı. ISBN: 978-975-404-815-5.Üniversite Yayın No: 4774.Cerrahpaşa Tıp Fak. Yayın No: 269:Istanbul, 2008,p.219- 227.2. Colman RW, Hırsh J, Moider VJ. Hemostasis and Trombosis, Basic Principles and Clinical Practise.6th ed.USA: Lippincott Williams,2004,p.381-400.
- 3. Carmona RH, Lim RC, Clark GC. Morbidity and mortality in hepatic trauma. Am J Surg 1982;144:88-94.
- 4. Kaynaroğlu ZV. Karın travmaları. Ed:Sayeki. Temel cerrahi.3th ed. Ankara: Güneş kitabevi. 2004,466-472.
- 5. Parks RW, Chrysos E, Diamond T. Management of liver trauma. Br J Surg 1999; 86: 1121-1135.
- 6. Secer HI, Daneyemez M, Tehli O, Gonul E, Izci Y. The clinical, electrophysiologic, and surgical characteristics of peripheral nerve injuries caused by gunshot wounds in adults: a 40-year experience. SurgNeurol 2008;69:143-52.
- 7. Sönmez E, Çavuş UY, Civelek C, Dur A, Karayel E, Gülen B, Uysal Ö, İpek G. The efficacy of a hemostatic agent in anticoagulant drug-induced rat bleeding model. Ulus Travma Acil Cerr Derg March 2014; 20: 2.
- 8. Kurata M, Horii I. Blood coagulation tests in toxicological studies review of methods and their significance for drug safety assesment. J.Toxical Sci 2004;29:13-32.
- 9. Daniel NG, Goulet J, Bergeron M, Paquin R, Landry Pe. Antitrombosit Drugs:ıs there a surgical risk? J can dent Assoc 2002;68:683-687.
- Degroot Pg, Sixma Jj. Trombosit Adhesion. Br J haematol 1990; 75:308-312.
- Goker H, Haznedaroglu IC, Ercetın S, Kırazlı S, Akman U, Ozturk Y, Hc Fırat HC. Haemostatic Actions of the Folkloric Medicinal Plant Extract Ankaferd Blood Stopper. The Journal of International Medical Research 2008; 36:163-170.
- Seyednejad H, Imani M, Jamieson T, Seifalian AM. Topical haemostatic agents. British Journal of Surgery 2008; 95: 1197-1225.
- 13. Pogorielov MV, Sikora VZ. Chitosan as a Hemostatic Agent: Current State. European Journal of Medicine. Series B, 2015, Vol.(2), Is. 1.
- 14. Lapierre F, Houtaud SD, Wager M, Hemostatic Agents in Neurosurgery. Explicative Cases of Controversial Issues in Neurosurger 2011,doi:10.5772/31319.
- Uzun N, Tanriverdi T, Savrun FK, Kiziltan ME, Sahin R, Hanimoglu H, et al. Traumatic peripheral nerve injuries: demographic and electrophysiologic findings of 802 patients from a developing country. J ClinNeuromuscul Dis 2006;7:97-103
- 16. Vance GN and Etheresia P. Iron-enhanced coagulation is attenuated by chelation:a thrombelastographic and ultrastructural analysis. Blood Coagulation and Fibrinolysis 2014;25:845–850.
- 17. Jankun J, Landeta P, Pretorıus E, Skrzypczak-Jankun E, Lıpınskı B. Unusual clotting dynamics of plasmasupplemented with iron(III). Internatıonal Journal Of Molecular Medıcıne 2014; 33: 367-372.
- Clark WR, Leather RP, Hemostasis during liver resections. Surgery 1970;67:5556-5576.
- Evans BE. Local hemostatic agents. N.Y. J. Dent 1977; 47: 109-14.
- Bleeding Control and Healing Aid Compositions and Methods of Use, Terence Prevendar, US 6,652,840 B1, Nov. 25, 2003.
- 21. Taylor CA, Braza D, Rice JB, Dillingham T. The incidence of peripheral nerve injury in extremity trauma. Am J Phys Med Rehabil 2008;87:381-5.
- Al B, Yildirim C, Cavdar M, Zengin S, Buyukaslan H, Kalender ME. Effectiveness of Ankaferd blood stopper in the topical control of active bleeding due to cutaneous-subcutaneous incisions. Saudi Med J 2009; 30: 1520–5.
- 23. Vance GN, Etheresia P. Iron-enhanced coagulation is attenuated by chelation:a thrombelastographic and ultrastructural analysis. Blood Coagulation and Fibrinolysis 2014;25:845–50.
- Aysan E, Bektas H, Ersoz F, Sari S, Kaygusuz A, Huq GE. Ability of the ankaferd blood stopper® to prevent parenchymal bleeding in an experimental hepatic trauma model. Int J Clin Exp Med 2010; 3: 186–91. 2.
- Beyazit Y, Kurt M, Kekilli M, Goker H, Haznedaroglu IC. Evaluation of hemostatic effects of Ankaferd as an alternative medicine. Altern Med Rev 2010; 15: 329–36. 3.
- Beyazit Y, Kekilli M, Haznedaroglu IC, Kayacetin E, Basaranoglu M. Ankaferd hemostat in the management of gastrointestinal hemorrhages. World J Gastroenterol 2011; 17: 3962–70. 4.
- 27. Tasdelen Fisgin N, Tanriverdi Cayci Y, Coban AY, Ozatli D, Tanyel E, Durupinar B, Tulek N. Antimicrobial activity of plant extract Ankaferd Blood Stopper. Fitoterapia 2009; 80: 48–50. 5.
- Kandemir O, Buyukates M, Kandemir NO, Aktunc E, Gul AE, Gul S, Turan SA. Demonstration of the histopathological and immunohistochemical effects of a novel hemostatic agent, Ankaferd Blood Stopper, on vascular tissue in a rat aortic bleeding model. J Cardiothorac Surg 2010; 5: 110. 6.
- Yüce S, Çandirli C, Yenidünya S, Muslu B. New hemostatic agent: the effect of Ankaferd Blood Stopper on healing wounds in experimental skin incision model. Turk J Med Sci 2014; 44: 288-294.
Öz
Amaç: Kanamayı
durdurmak için hemostatik ajanların kullanılır. Tıpta, ideal
bir hemostatik ajan lezyona uygulandıktan sonra venöz kanamayı durdurmalıdır. Bu
çalışmada A-Fact’ın hemostatik parametrelerinin invitro etkileri
araştırılacaktır. Yöntem: İnsan
plazmasında farklı oranlarda belirlenmiştir. Hemostatik parametreler rutin
biyokimyasal yöntemler kullanılarak belirlendi. Tam kanda morfolojik
değerlendirme için kan örneklerine% 5,% 10,% 15 ve% 50 ilaçların mikroskobik
görüntüleri alındı. Bulgular:
A-Fact,
protein ağının çok hızlı oluşumunu sağladı. Koagülasyon testi 2/20 seyreltme
üzerinde yapıldı. Koagülasyon faktörü 2,7 ve 9 çalışıldı ve A-Fact koagülasyon
faktörlerini etkilemedi. . Plazma fibrinojen aktivitesi, total protein, albümin
ve globulin düzeyleri azalırken buna paralel olarak protrombin zamanı uzadı.
Ayrıca,
A-Fact eklendikten sonra INR değerleri artırıldı. Sonuç: Sonuçlarımıza göre; A-Fact kanama durdurucunun mekanizması
protein ağı oluşumunu gösterdi. Elde edilen veriler A-fact’ı yeni bir
hemostatik ajan olarak gösterdi.
Anahtar Kelimeler
Kaynakça
- 1. Ferhanoğlu B. Hemostaz Mekanizması. Hematoloji Ders Kitabı. ISBN: 978-975-404-815-5.Üniversite Yayın No: 4774.Cerrahpaşa Tıp Fak. Yayın No: 269:Istanbul, 2008,p.219- 227.2. Colman RW, Hırsh J, Moider VJ. Hemostasis and Trombosis, Basic Principles and Clinical Practise.6th ed.USA: Lippincott Williams,2004,p.381-400.
- 3. Carmona RH, Lim RC, Clark GC. Morbidity and mortality in hepatic trauma. Am J Surg 1982;144:88-94.
- 4. Kaynaroğlu ZV. Karın travmaları. Ed:Sayeki. Temel cerrahi.3th ed. Ankara: Güneş kitabevi. 2004,466-472.
- 5. Parks RW, Chrysos E, Diamond T. Management of liver trauma. Br J Surg 1999; 86: 1121-1135.
- 6. Secer HI, Daneyemez M, Tehli O, Gonul E, Izci Y. The clinical, electrophysiologic, and surgical characteristics of peripheral nerve injuries caused by gunshot wounds in adults: a 40-year experience. SurgNeurol 2008;69:143-52.
- 7. Sönmez E, Çavuş UY, Civelek C, Dur A, Karayel E, Gülen B, Uysal Ö, İpek G. The efficacy of a hemostatic agent in anticoagulant drug-induced rat bleeding model. Ulus Travma Acil Cerr Derg March 2014; 20: 2.
- 8. Kurata M, Horii I. Blood coagulation tests in toxicological studies review of methods and their significance for drug safety assesment. J.Toxical Sci 2004;29:13-32.
- 9. Daniel NG, Goulet J, Bergeron M, Paquin R, Landry Pe. Antitrombosit Drugs:ıs there a surgical risk? J can dent Assoc 2002;68:683-687.
- Degroot Pg, Sixma Jj. Trombosit Adhesion. Br J haematol 1990; 75:308-312.
- Goker H, Haznedaroglu IC, Ercetın S, Kırazlı S, Akman U, Ozturk Y, Hc Fırat HC. Haemostatic Actions of the Folkloric Medicinal Plant Extract Ankaferd Blood Stopper. The Journal of International Medical Research 2008; 36:163-170.
- Seyednejad H, Imani M, Jamieson T, Seifalian AM. Topical haemostatic agents. British Journal of Surgery 2008; 95: 1197-1225.
- 13. Pogorielov MV, Sikora VZ. Chitosan as a Hemostatic Agent: Current State. European Journal of Medicine. Series B, 2015, Vol.(2), Is. 1.
- 14. Lapierre F, Houtaud SD, Wager M, Hemostatic Agents in Neurosurgery. Explicative Cases of Controversial Issues in Neurosurger 2011,doi:10.5772/31319.
- Uzun N, Tanriverdi T, Savrun FK, Kiziltan ME, Sahin R, Hanimoglu H, et al. Traumatic peripheral nerve injuries: demographic and electrophysiologic findings of 802 patients from a developing country. J ClinNeuromuscul Dis 2006;7:97-103
- 16. Vance GN and Etheresia P. Iron-enhanced coagulation is attenuated by chelation:a thrombelastographic and ultrastructural analysis. Blood Coagulation and Fibrinolysis 2014;25:845–850.
- 17. Jankun J, Landeta P, Pretorıus E, Skrzypczak-Jankun E, Lıpınskı B. Unusual clotting dynamics of plasmasupplemented with iron(III). Internatıonal Journal Of Molecular Medıcıne 2014; 33: 367-372.
- Clark WR, Leather RP, Hemostasis during liver resections. Surgery 1970;67:5556-5576.
- Evans BE. Local hemostatic agents. N.Y. J. Dent 1977; 47: 109-14.
- Bleeding Control and Healing Aid Compositions and Methods of Use, Terence Prevendar, US 6,652,840 B1, Nov. 25, 2003.
- 21. Taylor CA, Braza D, Rice JB, Dillingham T. The incidence of peripheral nerve injury in extremity trauma. Am J Phys Med Rehabil 2008;87:381-5.
- Al B, Yildirim C, Cavdar M, Zengin S, Buyukaslan H, Kalender ME. Effectiveness of Ankaferd blood stopper in the topical control of active bleeding due to cutaneous-subcutaneous incisions. Saudi Med J 2009; 30: 1520–5.
- 23. Vance GN, Etheresia P. Iron-enhanced coagulation is attenuated by chelation:a thrombelastographic and ultrastructural analysis. Blood Coagulation and Fibrinolysis 2014;25:845–50.
- Aysan E, Bektas H, Ersoz F, Sari S, Kaygusuz A, Huq GE. Ability of the ankaferd blood stopper® to prevent parenchymal bleeding in an experimental hepatic trauma model. Int J Clin Exp Med 2010; 3: 186–91. 2.
- Beyazit Y, Kurt M, Kekilli M, Goker H, Haznedaroglu IC. Evaluation of hemostatic effects of Ankaferd as an alternative medicine. Altern Med Rev 2010; 15: 329–36. 3.
- Beyazit Y, Kekilli M, Haznedaroglu IC, Kayacetin E, Basaranoglu M. Ankaferd hemostat in the management of gastrointestinal hemorrhages. World J Gastroenterol 2011; 17: 3962–70. 4.
- 27. Tasdelen Fisgin N, Tanriverdi Cayci Y, Coban AY, Ozatli D, Tanyel E, Durupinar B, Tulek N. Antimicrobial activity of plant extract Ankaferd Blood Stopper. Fitoterapia 2009; 80: 48–50. 5.
- Kandemir O, Buyukates M, Kandemir NO, Aktunc E, Gul AE, Gul S, Turan SA. Demonstration of the histopathological and immunohistochemical effects of a novel hemostatic agent, Ankaferd Blood Stopper, on vascular tissue in a rat aortic bleeding model. J Cardiothorac Surg 2010; 5: 110. 6.
- Yüce S, Çandirli C, Yenidünya S, Muslu B. New hemostatic agent: the effect of Ankaferd Blood Stopper on healing wounds in experimental skin incision model. Turk J Med Sci 2014; 44: 288-294.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Temel Tıp Bilimleri Araştırma Yazıları |
| Yazarlar | |
| Yayımlanma Tarihi | 29 Aralık 2018 |
| Kabul Tarihi | 16 Aralık 2018 |
| Yayımlandığı Sayı | Yıl 2018Cilt: 40 Sayı: 4 |